TY - JOUR
T1 - Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia
AU - Gürman, G.
AU - Çelebi, H.
AU - Üstün, C.
AU - Arat, M.
AU - Ilhan, O.
AU - Özcan, M.
AU - Arslan, Ö
AU - Uysal, A.
AU - Akan, H.
AU - Beksaç, M.
AU - Konuk, N.
AU - Koç, H.
PY - 2001
Y1 - 2001
N2 - Allogeneic peripheral blood stem cell transplantation- (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.
AB - Allogeneic peripheral blood stem cell transplantation- (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.
KW - Allogeneic peripheral blood stem cell transplantation
KW - Severe aplastic anemia
UR - http://www.scopus.com/inward/record.url?scp=0035127188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035127188&partnerID=8YFLogxK
U2 - 10.1046/j.1526-0968.2001.005001054.x
DO - 10.1046/j.1526-0968.2001.005001054.x
M3 - Article
C2 - 11258612
AN - SCOPUS:0035127188
VL - 5
SP - 54
EP - 57
JO - Therapeutic Apheresis and Dialysis
JF - Therapeutic Apheresis and Dialysis
SN - 1744-9979
IS - 1
ER -
